CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction

European Journal of Clinical Pharmacology

Volumn 64, Issue 12, 2008, Pages 1163-1173

  Goryachkina, Ksenia ^a,b   Burbello, Aleksandra ^a   Boldueva, Svetlana ^a   Babak, Svetlana ^a   Bergman, Ulf ^b   Bertilsson, Leif ^b  

^a NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute myocardial infarction; CYP2D6; Drug disposition; In hospital treatment; Metoprolol; Therapeutic response

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA HYDROXYMETOPROLOL; AMLODIPINE; ATORVASTATIN; CLOPIDOGREL; CYTOCHROME P450 2D6; ENALAPRIL; FELODIPINE; FOSINOPRIL; FUROSEMIDE; GLIBENCLAMIDE; GLICLAZIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRON DERIVATIVE; LISINOPRIL; METFORMIN; METOPROLOL; NIFEDIPINE; NIMODIPINE; OMEPRAZOLE; PERINDOPRIL; QUINAPRIL; REPAGLINIDE; ROSUVASTATIN; SIMVASTATIN; SPIRONOLACTONE; TRIMETAZIDINE; UNINDEXED DRUG; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRADYCARDIA; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; FEMALE; GENE DUPLICATION; GENOTYPE; HEART EJECTION FRACTION; HEART RATE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; RUSSIAN FEDERATION; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; FEMALE; GENE DUPLICATION; GENOTYPE; HEART RATE; HOSPITALIZATION; HUMANS; MALE; METABOLIC CLEARANCE RATE; METOPROLOL; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RUSSIA; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 57049179618     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0525-3     Document Type: Article

References (37)

1. WHOSTAT (2005)
2. EM Antman DT Anbe PW Armstrong 2004 ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction) Circulation 110 9 e82 e292
3. J Herlitz BW Karlson A Hjalmarson 1993 Ten-year mortality rate after development of acute myocardial infarction in relation to clinical history and observations during hospital stay: experience from the Goteborg metoprolol trial Coron Artery Dis 4 12 1077 1083
4. MS Lennard JH Silas S Freestone 1982 Oxidation phenotype-a major determinant of metoprolol metabolism and response N Engl J Med 307 25 1558 1560
5. L Bertilsson 2007 Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects Clin Pharmacol Ther 82 5 606 609
6. K Goryachkina A Burbello S Boldueva 2008 Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI) Eur J Clin Pharmacol 64 3 275 282
7. KJ Livak 1999 Allelic discrimination using fluorogenic probes and the 5' nuclease assay Genet Anal 14 5-6 143 149
8. M Garcia-Barcelo LY Chow HF Chiu 2000 Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population Clin Chem 46 1 18 23
9. E Lundqvist I Johansson M Ingelman-Sundberg 1999 Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes Gene 226 2 327 338
10. LD Bradford 2002 CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants Pharmacogenomics 3 2 229 243
11. EA Gaikovitch I Cascorbi PM Mrozikiewicz 2003 Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population Eur J Clin Pharmacol 59 4 303 312
12. Opie L (2005) Drugs for the heart 6th edition
13. Astra Zeneca FDA report NDA 19-962/S-027. 2005 [cited January, 2008]; Available from: http://redpoll.pharmacy.ualberta.ca/drugbank/drugBank/ FDA_labels/019962.pdf.
14. WJ Elliot 2001 Cyclic and circadian variations in cardiovascular events Am J Hypertens 14 9 Pt 2 291S 295S
15. T Rau R Heide K Bergmann 2002 Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment Pharmacogenetics 12 6 465 472
16. R Ismail LK Teh 2006 The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients J Clin Pharm Ther 31 1 99 109
17. L Bertilsson ML Dahl P Dalen 2002 Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs Br J Clin Pharmacol 53 2 111 122
18. R Koytchev RG Alken V Vlahov 1998 Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol Eur J Clin Pharmacol 54 6 469 474
19. CG Regardh G Johnsson 1980 Clinical pharmacokinetics of metoprolol Clin Pharmacokinet 5 6 557 569
20. M Packer MA Lukas DM Tenero 2006 Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction Am J Cardiol 98 7A 39L 45L
21. PA Thurmann S Haack U Werner 2006 Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent Clin Pharmacol Ther 80 5 551 553
22. AB Luzier A Killian JH Wilton 1999 Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers Clin Pharmacol Ther 66 6 594 601
23. PA Rochon GM Anderson JV Tu 1999 Use of beta-blocker therapy in older patients after acute myocardial infarction in Ontario CMAJ 161 11 1403 1408
24. G Olsson J Wikstrand I Warnold 1992 Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials Eur Heart J 13 1 28 32
25. KC Park DE Forman JY Wei 1995 Utility of beta-blockade treatment for older postinfarction patients J Am Geriatr Soc 43 7 751 755
26. J Herlitz A Hjalmarson S Holmberg 1985 Tolerability to treatment with metoprolol in acute myocardial infarction in relation to age Acta Med Scand 217 3 293 298
27. CG Regardh S Landahl M Larsson 1983 Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals Eur J Clin Pharmacol 24 2 221 226
28. ES Dimenas CG Dahlof B Heibel 1990 Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects-a comparison with atenolol Eur J Clin Pharmacol 38 6 571 578
29. KE Ellison G Gandhi 2005 Optimising the use of beta-adrenoceptor antagonists in coronary artery disease Drugs 65 6 787 797
30. CM Pratt SC Yepsen MG Bloom 1983 Evaluation of metoprolol in suppressing complex ventricular arrhythmias Am J Cardiol 52 1 73 78
31. DP Zipes AJ Camm M Borggrefe 2006 ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 10 e385 e484
32. M Frossard I Fuchs JM Leitner 2004 Platelet function predicts myocardial damage in patients with acute myocardial infarction Circulation 110 11 1392 1397
33. F Laghrissi-Thode WR Wagner BG Pollock 1997 Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease Biol Psychiatry 42 4 290 295
34. RH Elbekai AO El-Kadi 2006 Cytochrome P450 enzymes: central players in cardiovascular health and disease Pharmacol Ther 112 2 564 587
35. AM Yu JR Idle T Herraiz 2003 Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase Pharmacogenetics 13 6 307 319
36. L Bertilsson C Alm C De Las Carreras 1989 Debrisoquine hydroxylation polymorphism and personality Lancet 1 8637 555
37. A Llerena G Edman J Cobaleda 1993 Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6 Acta Psychiatr Scand 87 1 23 28